Overview

A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitiv

Status:
Recruiting

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

Phase:

Phase 3

Details

Lead Sponsor:

Debiopharm International SA

Collaborator:

GORTEC (Head and Neck Oncology and Radiotherapy Group)

Treatments:

Cisplatin